Narrow search
Showing 1 - 2 of 2
Cover Image
Cost-Effectiveness Analyses of Natalizumab (Tysabri(R)) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
Gani, Ray; Giovannoni, Gavin; Bates, David; Kemball, Belinda - In: PharmacoEconomics 26 (2008) 7, pp. 617-627
Background: Natalizumab (Tysabri(R)) is a new disease-modifying therapy that has been shown to be clinically effective in patients with relapsing-remitting multiple sclerosis (RRMS) and has been licensed for use in patients with highly active RRMS (HARRMS). These patients are those who...
Persistent link: https://www.econbiz.de/10005404771
Cover Image
Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
Gani, Ray; Giovannoni, Gavin; Bates, David; Kemball, Belinda - In: PharmacoEconomics 26 (2008) 7, pp. 617-627
If UK society is willing to pay more than £8200 per QALY, or Health and Social Services are willing to pay more than £26 000 per QALY, this analysis suggests that natalizumab is likely to be a cost-effective treatment for all patients with HARRMS. </AbstractSection> Copyright Adis Data Information BV 2008
Persistent link: https://www.econbiz.de/10011001431